reports
Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agre...
Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc. NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc. (“NeuBase”) were approved by Ohr’s stockholders at a special meeting held on July 10, 2019. As previously announced on January 3, 2019, the proposed merger will create a public company under which the stockholders of NeuBase will become majority holders of the combined company. Upon closing of t...
Ohr Pharmaceutical Urges Stockholders to Vote “FOR†Merger with Ne...
Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019 -- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every Vote Is Important to Avoid Delay in Completion of the Merger NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) reiterated the unanimous recommendation of its Board of Directors that stockholders vote “FOR” all of ...
Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Qua...
Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019 Preliminary proxy materials for the proposed merger with NeuBase Therapeutics filed with the SEC; Stockholder vote is expected to occur in the middle of calendar 2019 NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019. "We continue to be excited by the opportunity to merge with NeuBase Therapeutics, a privately-held biotechnology company developing next-genera...
Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed. Ohr Pharmaceutical Contact: Investor Relations ...
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quar...
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019 Stockholder vote on the proposed merger with NeuBase Therapeutics anticipated in the second calendar quarter of 2019 NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we announced the signing of a definitive agreement to merge with NeuBase Therapeutics, Inc., a privately-held biotechnology company, we have been working diligently to bring the proposed merger with...
Ohr Pharmaceutical Announces Reverse Stock Split to be Effective Febru...
Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019 Previously announced merger with NeuBase Therapeutics remains on track NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share. The Company's stockholders approved the reverse stock split at the Company's special meeting of shareholders held on January 18, 2019. The Company's common stock is...
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Thera...
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc. Proposed combined company's peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform enables rapid development of therapies delivered systemically for genetic diseases Initial indications include RNA gene silencing for Huntington’s disease and myotonic dystrophy, with additional future applications in other RNA silencing indications Ohr Pharmaceutical Reports Fiscal Year 2018 Financial Results Conference call and webcast to be held today, Jan. 3, at 8:30 a.m. EST NEW YORK, Jan. 03, 2...
Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results
Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its fiscal third quarter ended June 30, 2018. “We continue to work with our advisor to pursue strategic alternatives with the goal of maximizing shareholder value,” said Dr. Jason Slakter, chief executive officer of Ohr Pharmaceutical. “We look forward to updating the market on our progress.” Financial Results for the Third Q...
The Klein Law Firm Reminds Investors of Commencement of a Class Action...
NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) who purchased shares between June 24, 2014 and January 4, 2018. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statem...
OHRP EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors o...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ohr Pharmaceutical, Inc. ("Ohr") (NASDAQ:OHRP) securities between June 24, 2014 and January 4, 2018. Click here to learn about the case: http://www.wongesq.com/pslra-c/ohr-pharmaceutical-inc?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period, ...
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Co...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) between June 24, 2014 and January 4, 2018. You are hereby notified that Levi & Korsinsky has commenced the class action Khanna v. Ohr Pharmaceutical, Inc. (Case No. 1:18-cv-01284) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra-d/ohr-pharmaceutical-i...
The Klein Law Firm Announces Commencement of a Class Action Filed on B...
NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) who purchased shares between June 24, 2014 and January 4, 2018. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statem...
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to se...
OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suff...
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OHR Pharmaceutical, Inc. (“OHR” or the “Company”) (NASDAQ:OHRP). On January 4, 2018, OHR issued a press release announcing negative results from its study evaluating the safety and efficacy of Squalamine, the Company’s leading therapeutic candidate for improving vision outcomes in patients suffering from ophthalmic diseases. Specifically, patients receiving the Squalamine combination therapy fail...
OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investor...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ohr Pharmaceutical, Inc. ("Ohr") (NASDAQ: OHRP) securities between June 24, 2014 and January 4, 2018. Click here to learn about the case: http://www.wongesq.com/pslra-c/ohr-pharmaceutical-inc?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period,...
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) between June 24, 2014 and January 4, 2018. You are hereby notified that Levi & Korsinsky has commenced the class action Khanna v. Ohr Pharmaceutical, Inc. (Case No. 1:18-cv-01284) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra-d/ohr-pharmaceutical-...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to se...
The Klein Law Firm Reminds Investors of an Investigation Regarding Pos...
NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces the commencement of an investigation of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) concerning possible violations of federal securities laws. On January 5, 2018, Ohr Pharmaceutical announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr Pharmaceutical announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr Pharmaceutical fell from a close of $2.02 on J...
OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suff...
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OHR Pharmaceutical, Inc. (“OHR” or the “Company”) (NASDAQ:OHRP). On January 4, 2018, OHR issued a press release announcing negative results from its study evaluating the safety and efficacy of Squalamine, the Company’s leading therapeutic candidate for improving vision outcomes in patients suffering from ophthalmic diseases. Specifically, patients receiving the Squalamine combination therapy fail...
The Klein Law Firm Notifies Investors of an Investigation Concerning P...
NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces the commencement of an investigation of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) concerning possible violations of federal securities laws. On January 5, 2018, Ohr Pharmaceutical announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr Pharmaceutical announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr Pharmaceutical fell from a close of $2.02 on Ja...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.